Moderna says its COVID-19 vaccine strongly protects kids as young as 12. The company released the preliminary findings Tuesday based on testing on more than 3,700 12- to 17-year-olds in the United States.
[02:05.99]It appeared 80 percent effective in preventing symptomatic COVID-19, [02:12.44]although that was based on just 10 cases found among study participants. [02:18.92]The number could change as Pfizer's study conti...
Moderna said it is looking at whether a booster shot – either of its existing vaccine or of a new shot designed to protect against the South Africa variant – could be made available in future if evidence were to emerge that protection against the virus deteriorated over time....
Moderna COVID-19 clinical considerations. (Source: RI DoH) The two vaccines are very similar and both are based on mRNA technology, but there are some important differences. The Pfizer vaccine is approved for patients age 16 and older, while the Moderna vaccine is approved for patients age 18...
company Moderna submitted a request to the U.S. Food and Drug Administration (FDA) on Thursday for emergency use authorization (EUA) on a fourth dose of its COVID-19 vaccine for adults 18 years of age and older, who already received a booster dose of any approved or authorized shot. ...
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial. mRNA-1273.214 stimulated almost twice the neutralising antibody lev
Unlike the mRNA vaccines from Pfizer and Moderna, the Novavax shot uses a more traditional vaccine technology.By Don RaufSeptember 04, 2024 Updated COVID Vaccines for 2024–2025 Get FDA Approval Experts say the reformulated shots provide better protection against the variants that are still driving...
The Swiss drugmaker also produces ingredients for Moderna in the United States. Sweden's Recipharm, Samsung Biologics as well as ThermoFisher , which inked a deal with Moderna this week, also have roles in making the shot.
The FDA is looking to quickly approve Moderna’s coronavirus vaccine after it was unanimously backed by a panel of experts.
All six cases occurred in women ages 18 to 48, with symptoms developing six to 13 days after they received the shot. Doctors typically treat that type of blood clot with heparin, but health regulators noted that could be dangerous in this case and recommended a differe...